North America Gastric Cancer Drugs Market Report and Forecast 2024-2032

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions
    1.3    Report Coverage – Key Segmentation and Scope 
    1.4    Research Methodology                  
2    Executive Summary
3    North America Gastric Cancer Drugs Market Overview 
    3.1    North America Gastric Cancer Drugs Market Historical Value (2017-2023) 
    3.2    North America Gastric Cancer Drugs Market Forecast Value (2024-2032)
4    North America Gastric Cancer Drugs Market Landscape*
    4.1    North America Gastric Cancer Drugs Market: Developers Landscape
        4.1.1    Analysis by Year of Establishment
        4.1.2    Analysis by Company Size
        4.1.3    Analysis by Region
    4.2    North America Gastric Cancer Drugs Market: Product Landscape
        4.2.1    Analysis by Therapy Type    
        4.2.2    Analysis by Diseases Type 
5    North America Gastric Cancer Drugs Market Dynamics
    5.1    Market Drivers and Constraints
    5.2    SWOT Analysis
        5.2.1    Strengths
        5.2.2    Weaknesses
        5.2.3    Opportunities
        5.2.4    Threats
    5.3    Porter’s Five Forces Analysis
        5.3.1    Bargaining Power of Suppliers
        5.3.2    Bargaining Power of Buyers
        5.3.3    Threat of New Entrants
        5.3.4    Threat of Substitutes
        5.3.5    Degree of Rivalry
    5.4    Key Demand Indicators 
    5.5    Key Price Indicators
    5.6    Industry Events, Initiatives, and Trends  
    5.7    Value Chain Analysis
6    North America Gastric  Cancer Drugs Market Segmentation (2017-2032)
    6.1    North America Gastric Cancer Drugs Market (2017-2032) by Therapy Type
        6.1.1    Market Overview
        6.1.2    Chemotherapy
        6.1.3    Targeted Therapy
        6.1.4    Immunotherapy
        6.1.5    Radiation Therapy
        6.1.6    Surgery
        6.1.7    Others
    6.2    North America Gastric Cancer Drugs Market (2017-2032) by Disease Type
        6.2.1    Market Overview
        6.2.2    Adenocarcinoma
        6.2.3    Lymphoma
        6.2.4    Gastrointestinal Stromal Tumor
        6.2.5    Carcinoid Tumor
        6.2.6    Others
    6.3    North America Gastric Cancer Drugs Market (2017-2032) by Drug Class
        6.3.1    Market Overview
        6.3.2    PD-1/PD-L1 Inhibitors 
        6.3.3    HER2 Antagonists
        6.3.4    VEGFR2 Antagonists
        6.3.5    Others
    6.4    North America Gastric Cancer Drugs Market (2017-2032) by Route 0f Administration
        6.4.1    Market Overview
        6.4.2    Oral 
        6.4.3    Injectable
    6.5    North America Gastric Cancer Drugs Market (2017-2032) by End Use 
        6.5.1    Market Overview
        6.5.2    Ambulatory Surgery Centers
        6.5.3    Hospitals and Specialty Clinics
        6.5.4    Others
    6.6    North America Gastric Cancer Drugs Market (2017-2032) by Distribution Channel 
        6.6.1    Market Overview
        6.6.2    Hospital Pharmacies
        6.6.3    Specialty and Retail Pharmacies
        6.6.4    Others
    6.7    North America Gastric Cancer Drugs Market (2017-2032) by Countries
        6.7.1    Market Overview
        6.7.2    United States of America
        6.7.3    Canada
7    United States of  America Gastric Cancer Drugs Market (2017-2032)
    7.1    United States of America Gastric Cancer Drugs Market (2017-2032) by Therapy Type
        7.1.1    Market Overview
        7.1.2    Chemotherapy
        7.1.3    Targeted Therapy
        7.1.4    Immunotherapy
        7.1.5    Radiation Therapy
        7.1.6    Surgery
        7.1.7    Others
    7.2    United States of America Gastric Cancer Drugs Market (2017-2032) by Disease Type
        7.2.1    Market Overview
        7.2.2    Adenocarcinoma
        7.2.3    Lymphoma
        7.2.4    Gastrointestinal Stromal Tumor
        7.2.5    Carcinoid Tumor
        7.2.6    Others
    7.3    United States of America Gastric Cancer Drugs Market (2017-2032) by Drug Class
        7.3.1    Market Overview
        7.3.2    PD-1/PD-L1 Inhibitors 
        7.3.3    HER2 Antagonists
        7.3.4    VEGFR2 Antagonists
        7.3.5    Others
    7.4    United States of America Gastric Cancer Drugs Market (2017-2032) by Route 0f Administration
        7.4.1    Market Overview
        7.4.2    Oral 
        7.4.3    Injectable
    7.5    United States of America Gastric Cancer Drugs Market (2017-2032) by End Use 
        7.5.1    Market Overview
        7.5.2    Ambulatory Surgery Centers
        7.5.3    Hospitals and Specialty Clinics
        7.5.4    Others
    7.6    United States of America Gastric Cancer Drugs Market (2017-2032) by Distribution Channel 
        7.6.1    Market Overview
        7.6.2    Hospital Pharmacies
        7.6.3    Specialty and Retail Pharmacies
        7.6.4    Others
8    Canada Gastric Cancer Drugs Market (2017-2032)
    8.1    Canada Gastric Cancer Drugs Market (2017-2032) by Therapy Type
        8.1.1    Market Overview
        8.1.2    Chemotherapy
        8.1.3    Targeted Therapy
        8.1.4    Immunotherapy
        8.1.5    Radiation Therapy
        8.1.6    Surgery
        8.1.7    Others
    8.2    Canada Gastric Cancer Drugs Market (2017-2032) by Disease Type
        8.2.1    Market Overview
        8.2.2    Adenocarcinoma
        8.2.3    Lymphoma
        8.2.4    Gastrointestinal Stromal Tumor
        8.2.5    Carcinoid Tumor
        8.2.6    Others
    8.3    Canada Gastric Cancer Drugs Market (2017-2032) by Drug Class
        8.3.1    Market Overview
        8.3.2    PD-1/PD-L1 Inhibitors 
        8.3.3    HER2 Antagonists
        8.3.4    VEGFR2 Antagonists
        8.3.5    Others
    8.4    Canada Gastric Cancer Drugs Market (2017-2032) by Route 0f Administration
        8.4.1    Market Overview
        8.4.2    Oral 
        8.4.3    Injectable
    8.5    Canada Gastric Cancer Drugs Market (2017-2032) by End Use 
        8.5.1    Market Overview
        8.5.2    Ambulatory Surgery Centers
        8.5.3    Hospitals and Specialty Clinics
        8.5.4    Others
    8.6    Canada Gastric Cancer Drugs Market (2017-2032) by Distribution Channel 
        8.6.1    Market Overview
        8.6.2    Hospital Pharmacies
        8.6.3    Specialty and Retail Pharmacies
        8.6.4    Others
9    Regulatory Framework
10    Patent Analysis
    10.1     Analysis by Type of Patent
    10.2     Analysis by Publication year
    10.3     Analysis by Issuing Authority
    10.4     Analysis by Patent Age
    10.5     Analysis by CPC Analysis
    10.6     Analysis by Patent Valuation 
    10.7     Analysis by Key Players
11    Funding and Investment Analysis
    11.1     Analysis by Funding Instances
    11.2     Analysis by Type of Funding
    11.3     Analysis by Funding Amount
    11.4     Analysis by Leading Players
    11.5     Analysis by Leading Investors
    11.6     Analysis by Geography
12    Partnership and Collaborations Analysis
    12.1     Analysis by Partnership Instances
    12.2     Analysis by Type of Partnership
    12.3     Analysis by Leading Players
    12.4     Analysis by Geography
13    Supplier Landscape
    13.1    Market Share by Top 5 Companies
    13.2    Novartis AG
        13.2.1    Financial Analysis
         13.2.2    Product Portfolio
        13.2.3    Demographic Reach and Achievements
        13.2.4    Mergers and Acquisitions
        13.2.5    Certifications 
    13.3    Pfizer, Inc.
        13.3.1    Financial Analysis
        13.3.2    Product Portfolio
        13.3.3    Demographic Reach and Achievements
        13.3.4    Mergers and Acquisitions
        13.3.5    Certifications
    13.4    Viatris, Inc 
        13.4.1    Financial Analysis
        13.4.2    Product Portfolio
        13.4.3    Demographic Reach and Achievements
        13.4.4    Mergers and Acquisitions
        13.4.5    Certifications
    13.5    F. Hoffmann- La Roche Ltd.
        13.5.1    Financial Analysis
        13.5.2    Product Portfolio
        13.5.3    Demographic Reach and Achievements
        13.5.4    Mergers and Acquisitions
        13.5.5    Certifications
    13.6    Eli Lilly and Company
        13.6.1    Financial Analysis
        13.6.2    Product Portfolio
        13.6.3    Demographic Reach and Achievements
        13.6.4    Mergers and Acquisitions
        13.6.5    Certifications
    13.7    Merck & Co., Inc
        13.7.1    Financial Analysis
        13.7.2    Product Portfolio
        13.7.3    Demographic Reach and Achievements
        13.7.4    Mergers and Acquisitions
        13.7.5    Certifications
    13.8    Teva Pharmaceutical Industries Ltd.
        13.8.1    Financial Analysis
        13.8.2    Product Portfolio
        13.8.3    Demographic Reach and Achievements
        13.8.4    Mergers and Acquisitions
        13.8.5    Certifications
    13.9    Bristol Myers Squibb Company
        13.9.1    Financial Analysis
        13.9.2    Product Portfolio
        13.9.3    Demographic Reach and Achievements
        13.9.4    Mergers and Acquisitions
        13.9.5    Certifications
    13.10    Celltrion Healthcare Co., Ltd.
        13.10.1    Financial Analysis
        13.10.2    Product Portfolio
        13.10.3    Demographic Reach and Achievements
        13.10.4    Mergers and Acquisitions
        13.10.5    Certifications
    13.11    Samsung Biologics Co., Ltd.
        13.11.1    Financial Analysis
        13.11.2    Product Portfolio
        13.11.3    Demographic Reach and Achievements
        13.11.4    Mergers and Acquisitions
        13.11.5    Certifications
14    North America Gastric Cancer Drugs Market – Distribution Model (Additional Insight)
    14.1     Overview 
    14.2     Potential Distributors 
    14.3     Key Parameters for Distribution Partner Assessment 
15    Key Opinion Leaders (KOL) Insights (Additional Insight)
16    Company Competitiveness Analysis (Additional Insight)
    16.1     Very Small Companies
    16.2     Small Companies
    16.3     Mid-Sized Companies
    16.4     Large Companies
    16.5     Very Large Companies
17    Payment Methods (Additional Insight)
    17.1     Government Funded
    17.2     Private Insurance
    17.3     Out-of-Pocket

*Additional insights provided are customisable as per client requirements.

* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.